CA
NZ
UK
AU
IND
US
SAB Biotherapeutics (NASDAQ: SABS) announced a collaboration with Breakthrough T1D to advance its SAB-142 therapy for Stage 3 type 1 diabetes. The grant supports the PRISE-hATG clinical study, led by Dr. Michael J. Haller at the University of Florida, targeting patients recently diagnosed with …
Galera Therapeutics Inc. Has received board approval for a 1-for-200 reverse stock split of its common stock, par value $0.001. The decision aligns with the company’s strategic objectives as it advances its clinical programs targeting radiation-induced side effects in cancer treatment.
Greater Cannabis Company Inc. (OTC: GCAN) has experienced a major shift in governance, as Trafalgar Asset Management, LLC has established a commanding position in the company’s voting structure. This development follows the firm’s accumulation of a dominant stake in the company’s securities, reflecting a …
Healthy Extracts Inc. Faces a leadership transition after its president and chief operating officer resigned. The move leaves critical executive positions vacant as the company works to maintain operational continuity.
IGC Pharma, Inc. (NYSE American: IGC) disclosed that its chief executive officer, Ram Mukunda, and its vice president and principal financial officer, Claudia Grimaldi, each purchased newly issued common stock directly from the Company. The transactions convert personal advances totaling $1,154,210 into restricted shares …
Invivyd (NASDAQ: IVVD) faces a regulatory shift as the FDA signals the end of PEMGARDA’s Emergency Use Authorization in the forthcoming year. The biotech firm disclosed the advance notice recently, marking a pivotal moment for its prevention strategy.
Kalaris Therapeutics, Inc. (NASDAQ: KLRS) disclosed a shift in its board composition on July 3 2026. The company confirmed that Dr. Morana Jovan‑Embiricos stepped down from both the board and its audit committee, and that Laurie Keating was elected to replace her effective August …
Longeveron (NASDAQ: LGVN) has named Marie Washburn as its new chief financial officer, effective July 13, as the clinical‑stage biotech prepares for a pivotal phase in its development. The appointment follows the departure of former CFO Lisa Locklear, who stepped down on July 10 …
Coda Octopus Group has announced a key leadership transition with the appointment of Mark Kelly as its new Chief Financial Officer. This change follows the planned retirement of current Interim CFO Gayle Jardine, who will leave her position on August 3, 2026. Kelly’s appointment …
AbCellera Biologics Inc. (NASDAQ: ABCL) recently announced the appointment of Dr. Lynn Seely to its Board of Directors. The addition of Dr.
Please wait processing your request...